Crowdonomics
WatchlistPortfolio
All companies
Intrommune Therapeutics, Inc. logo

Intrommune Therapeutics, Inc.

Operating

Biotech · New York, NY

Visit website
Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$3,714,689
Crowd $158K · Private $3.6M · 5 rounds since 2018

Financials

FY2016–FY2020 · from SEC filings · hover any figure for its source
$0
−$53K
2016
$0
−$138K
2017
$0
−$414K
2018
$0
−$414K
2019
$0
−$354K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016 reviewed*
FY2017 reviewed*
FY2018
FY2019 unaudited
FY2020 unaudited
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
Net income
-$52,833
-$137,567
-$414,112
-$414,112
-$354,179
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$200
$25,015
$25,015
$154,906
Accounts receivable
$0
$0
$1,499
$1,499
$0
Total assets
$0
$13,367
$543,049
$543,049
$751,006
Short-term debt
$0
$0
$145,454
$145,454
$0
Long-term debt
$0
$0
$290,264
$290,264
$290,264
Total liabilities
$0
$0
$435,718
$435,718
$290,264
Other
Headcount
—
4
2
—
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Fundraising history

Rule 506(b) · Convertible Note · Dec 2023Closed
Raised $210KInvestors 7
Rule 506(b) · Convertible Note · Mar 2022Closed
Raised $3.3MInvestors 15
Rule 506(c) · Equity · Jul 2021Closed
Raised $68KInvestors 6
Reg CF · Class A Membership Units · Apr 2018Closedvia Netcapital
Raised $157.8K / $1.1M

Team

2 people
Erick Berglund
Board Member
Michael Nelson
Principal Executive Officer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 8 annual reports (FY2018–FY2025)

15 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 12 filings on EDGAR
  • Form DJan 22, 20240001104659-24-005583
    EDGAR
  • Form DJan 22, 20240001104659-24-005581
    EDGAR
  • Form D/AJul 8, 20210001104659-21-089937
    EDGAR
  • Form DJun 23, 20210001104659-21-084552
    EDGAR
  • Form C-TRApr 28, 20210001104659-21-056317
    EDGAR
  • Form C-ARJun 15, 20200001104659-20-073368
    EDGAR
  • Form C-ARApr 30, 20190001144204-19-022336
    EDGAR
  • Form C-UJul 6, 20180001669191-18-000346
    EDGAR
Source: SEC EDGARCIK 0001736977DELast synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.